121
Filter
  • Disease Areas
    • All
    • Acute Lymphoblastic Leukemia
    • Acute Myeloid Leukemia
    • Adenoid Cystic Carcinoma
    • Adrenal Cortical Carcinoma
    • Aggressive Systemic Mastocytosis
    • Anaplastic Large Cell Non-Hodgkin´s Lymphoma
    • Basal Cell Carcinoma
    • Bladder Cancer
    • Breast Cancer
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
    • Chronic Myelomonocytic Leukemia
    • Colorectal Cancer
    • Cushing's Syndrome
    • Diffuse Large B-Cell Lymphoma
    • Endometrial Cancer
    • Essential Thrombocythemia
    • Exploratory - Hemat. Tumors
    • Exploratory - Solid Tumors
    • Fallopian Tube Cancer
    • Gastric Cancer
    • Gastroesophageal Junction Cancer
    • Gastrointestinal Stromal Tumor
    • Giant Cell Tumor of Bone
    • Glioblastoma Multiforme
    • Head and Neck Cancer
    • Head and Neck Squamous Cell Carcinoma
    • Hepatocellular Carcinoma
    • Hodgkin's Lymphoma
    • Inflammatory Myfibroblastic Tumors
    • Leukemia
    • Lymphoma
    • Malignant Rhabdoid Tumors
    • Mantle Cell Lymphoma
    • Mast Cell Leukemia
    • Medulloblastoma
    • Melanoma
    • Meningioma
    • Mesothelioma
    • Multiple Myeloma
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Neuroblastoma
    • Neuroendocrine Tumors
    • Non-Hodgkin Lymphoma
    • Non-Small Cell Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Paragangliomas
    • Peritoneal Cancer
    • Polycythemia Vera
    • Prostate Cancer
    • Renal Cell Carcinoma
    • Sarcoma
    • Small Cell Lung Cancer
    • Von Hippel-Lindau Syndrome
  • Development Phase
    • All
    • N/A
    • Phase 0
    • Phase 1
    • Phase 1/Phase 2
    • Phase 2
    • Phase 3
    • Phase 4
  • Pathways
    • All
    • ADORA2A Receptor Inhibitor
    • AKT Signaling
    • Angiogenesis Signaling
    • BCL2 Inhibition
    • BCR-ABL1 Inhibitor
    • CSF1 Inhibitor
    • Cortisol Effects
    • HDM2-p53 Interaction
    • IAP System
    • IL15RA Receptor Inhibitor
    • Immune Priming
    • Immune T-Cell Modulation
    • Immune Tumor Microenvironment
    • JAK/STAT Signaling
    • LAG-3 Inhibitor
    • MAPK Signaling
    • Microtubule Targeting Via P-CAD
    • Mutant EGFR Inhibitor
    • Mutant IDH1 inhibitor
    • PD-1 Inhibitor
    • RAS Signaling
    • RTK Signaling
    • SERD
    • STING Pathway
    • TIM-3 Receptor Inhibitor
    • anti-GITR
    • c-MET Signaling
    • cKIT Signaling
Nothing matches your selections.
  • ACUTE LYMPHOBLASTIC LEUKEMIA
  • Acute Lymphoblastic Leukemia Midostaurin (PKC412) A tyrosine kinase inhibitor targeting FLT-3, c-KIT, and several other kinase
  • Acute Lymphoblastic Leukemia ABL001 Phase 1 Allosteric Inhibition of BCR-ABL1
  • ACUTE MYELOID LEUKEMIA
  • Acute Myeloid Leukemia Midostaurin (PKC412) N/A A tyrosine kinase inhibitor targeting FLT-3, c-KIT, and several other kinase
  • Acute Myeloid Leukemia Midostaurin (PKC412) Phase 2 A tyrosine kinase inhibitor targeting FLT-3, c-KIT, and several other kinase
  • Acute Myeloid Leukemia PIM447 Phase 1 Inhibiting PIM Kinases
  • AGGRESSIVE SYSTEMIC MASTOCYTOSIS
  • Aggressive Systemic Mastocytosis Midostaurin (PKC412) A tyrosine kinase inhibitor targeting FLT-3, c-KIT, and several other kinase
  • BREAST CANCER
  • Breast Cancer Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Breast Cancer Alpelisib (BYL719) Phase 2 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Breast Cancer Alpelisib (BYL719) Phase 3 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Breast Cancer Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Breast Cancer Buparlisib (BKM120) Phase 2 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Breast Cancer LSZ102 Phase 1 A selective estrogen receptor downregulator
  • Breast Cancer LCL161 Phase 1 Inhibitor of Apoptosis Proteins (IAPs)
  • Breast Cancer LJM716 Phase 1 Targeting Human Epidermal Growth Factor Receptor 3 (HER3) with a fully human anti-HER3 IgG1 antibody
  • Breast Cancer MCS110 Phase 2 A Humanized Anti-Colony-Stimulating Factor (CSF-1) Monoclonal Antibody
  • Breast Cancer PCA062 Phase 1 Antibody-drug conjugate targeting P-cadherin
  • Breast Cancer Ribociclib (LEE011) Phase 3 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Breast Cancer Alpelisib (BYL719) Phase 1 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Breast Cancer Ribociclib (LEE011) Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Breast Cancer Ribociclib (LEE011) Phase 1 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • CHRONIC MYELOID LEUKEMIA
  • Chronic Myeloid Leukemia ABL001 Phase 1 Allosteric Inhibition of BCR-ABL1
  • Chronic Myeloid Leukemia ABL001 Phase 3 Allosteric Inhibition of BCR-ABL1
  • COLORECTAL CANCER
  • Colorectal Cancer Alpelisib (BYL719) Phase 1 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Colorectal Cancer Buparlisib (BKM120) Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • CUSHING'S SYNDROME
  • Cushing's Syndrome Osilodrostat (LCI699) Phase 2 11beta-hydroxylase inhibitor
  • Cushing's Syndrome Osilodrostat (LCI699) Phase 3 11beta-hydroxylase inhibitor
  • DIFFUSE LARGE B-CELL LYMPHOMA
  • Diffuse Large B-Cell Lymphoma Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Diffuse Large B-Cell Lymphoma Ribociclib (LEE011) Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • ENDOMETRIAL CANCER
  • Endometrial Cancer Buparlisib (BKM120) Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • EXPLORATORY - HEMAT. TUMORS
  • Exploratory - Hemat. Tumors PIM447 Inhibiting PIM Kinases
  • Exploratory - Hemat. Tumors LCL161 Inhibitor of Apoptosis Proteins (IAPs)
  • Exploratory - Hemat. Tumors HDM201 Phase 1 HDM2-p53 interaction
  • Exploratory - Hemat. Tumors GWN323 An anti-GITR pathway agonist antibody
  • EXPLORATORY - SOLID TUMORS
  • Exploratory - Solid Tumors Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Exploratory - Solid Tumors NIZ985 Recombinant human heterodimeric IL-15
  • Exploratory - Solid Tumors FGF401 Inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4)
  • Exploratory - Solid Tumors PDR001 Phase 1 A PD-1 receptor-targeting monoclonal antibody
  • Exploratory - Solid Tumors PDR001 Phase 1/Phase 2 A PD-1 receptor-targeting monoclonal antibody
  • Exploratory - Solid Tumors PDR001 Phase 2 A PD-1 receptor-targeting monoclonal antibody
  • Exploratory - Solid Tumors IDH305 Phase 1 Inhibitor of mutant IDH1
  • Exploratory - Solid Tumors Capmatinib (INC280) Phase 1 c-MET RTK inhibitor
  • Exploratory - Solid Tumors Capmatinib (INC280) Phase 2 c-MET RTK inhibitor
  • Exploratory - Solid Tumors Capmatinib (INC280) Phase 4 c-MET RTK inhibitor
  • Exploratory - Solid Tumors Alpelisib (BYL719) Phase 1 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Exploratory - Solid Tumors Alpelisib (BYL719) Phase 1/Phase 2 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Exploratory - Solid Tumors Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Exploratory - Solid Tumors Buparlisib (BKM120) Phase 2 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Exploratory - Solid Tumors BGJ398 Phase 1 FGFR inhibitors
  • Exploratory - Solid Tumors BGJ398 Phase 2 FGFR inhibitors
  • Exploratory - Solid Tumors LCL161 Inhibitor of Apoptosis Proteins (IAPs)
  • Exploratory - Solid Tumors LJM716 Targeting Human Epidermal Growth Factor Receptor 3 (HER3) with a fully human anti-HER3 IgG1 antibody
  • Exploratory - Solid Tumors MCS110 Phase 2 A Humanized Anti-Colony-Stimulating Factor (CSF-1) Monoclonal Antibody
  • Exploratory - Solid Tumors HDM201 Phase 1 HDM2-p53 interaction
  • Exploratory - Solid Tumors LAG525 Phase 1/Phase 2 A LAG-3 receptor-targeting monoclonal antibody
  • Exploratory - Solid Tumors PCA062 Antibody-drug conjugate targeting P-cadherin
  • Exploratory - Solid Tumors MBG453 Phase 1/Phase 2 A TIM-3 inhibitor
  • Exploratory - Solid Tumors CGM097 HDM2-p53 interaction inhibitor
  • Exploratory - Solid Tumors GWN323 An anti-GITR pathway agonist antibody
  • Exploratory - Solid Tumors MIW815 A STING (simulator of interferon genes) antagonist
  • Exploratory - Solid Tumors PIM447 Inhibiting PIM Kinases
  • GASTRIC CANCER
  • Gastric Cancer LJM716 Phase 1 Targeting Human Epidermal Growth Factor Receptor 3 (HER3) with a fully human anti-HER3 IgG1 antibody
  • Gastric Cancer Afuresertib (ASB183) A pan-AKT kinase inhibitor
  • Gastric Cancer Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • GASTROESOPHAGEAL JUNCTION CANCER
  • Gastroesophageal Junction Cancer Buparlisib (BKM120) Phase 2 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Gastroesophageal Junction Cancer PCA062 Phase 1 Antibody-drug conjugate targeting P-cadherin
  • Gastroesophageal Junction Cancer Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • GASTROINTESTINAL STROMAL TUMOR
  • Gastrointestinal Stromal Tumor Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • GLIOBLASTOMA MULTIFORME
  • Glioblastoma Multiforme BGJ398 FGFR inhibitors
  • Glioblastoma Multiforme Buparlisib (BKM120) Phase 2 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • HEAD AND NECK CANCER
  • Head and Neck Cancer Buparlisib (BKM120) Phase 2 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Head and Neck Cancer Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • HEAD AND NECK SQUAMOUS CELL CARCINOMA
  • Head and Neck Squamous Cell Carcinoma LJM716 Targeting Human Epidermal Growth Factor Receptor 3 (HER3) with a fully human anti-HER3 IgG1 antibody
  • Head and Neck Squamous Cell Carcinoma PCA062 Antibody-drug conjugate targeting P-cadherin
  • Head and Neck Squamous Cell Carcinoma Alpelisib (BYL719) Phase 2 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Head and Neck Squamous Cell Carcinoma Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • HEPATOCELLULAR CARCINOMA
  • Hepatocellular Carcinoma Buparlisib (BKM120) Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Hepatocellular Carcinoma Capmatinib (INC280) Phase 1/Phase 2 c-MET RTK inhibitor
  • Hepatocellular Carcinoma FGF401 Phase 1/Phase 2 Inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4)
  • LEUKEMIA
  • Leukemia Midostaurin (PKC412) A tyrosine kinase inhibitor targeting FLT-3, c-KIT, and several other kinase
  • Leukemia LCL161 Phase 2 Inhibitor of Apoptosis Proteins (IAPs)
  • LYMPHOMA
  • Lymphoma MIW815 A STING (simulator of interferon genes) antagonist
  • Lymphoma Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Lymphoma Ribociclib (LEE011) Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Lymphoma GWN323 An anti-GITR pathway agonist antibody
  • MALIGNANT RHABDOID TUMORS
  • Malignant Rhabdoid Tumors Ribociclib (LEE011) Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • MANTLE CELL LYMPHOMA
  • Mantle Cell Lymphoma Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • MAST CELL LEUKEMIA
  • Mast Cell Leukemia Midostaurin (PKC412) A tyrosine kinase inhibitor targeting FLT-3, c-KIT, and several other kinase
  • MELANOMA
  • Melanoma BGJ398 FGFR inhibitors
  • Melanoma LAG525 A LAG-3 receptor-targeting monoclonal antibody
  • Melanoma Buparlisib (BKM120) Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Melanoma Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Melanoma Capmatinib (INC280) c-MET RTK inhibitor
  • Melanoma Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • MULTIPLE MYELOMA
  • Multiple Myeloma PIM447 Inhibiting PIM Kinases
  • Multiple Myeloma Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Multiple Myeloma LCL161 Phase 2 Inhibitor of Apoptosis Proteins (IAPs)
  • Multiple Myeloma Afuresertib (ASB183) A pan-AKT kinase inhibitor
  • MYELODYSPLASTIC SYNDROME
  • Myelodysplastic Syndrome PIM447 Phase 1 Inhibiting PIM Kinases
  • MYELOFIBROSIS
  • Myelofibrosis Buparlisib (BKM120) Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • NEUROBLASTOMA
  • Neuroblastoma Ribociclib (LEE011) Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • NON-SMALL CELL LUNG CANCER
  • Non-Small Cell Lung Cancer Capmatinib (INC280) Phase 1 c-MET RTK inhibitor
  • Non-Small Cell Lung Cancer Capmatinib (INC280) Phase 1/Phase 2 c-MET RTK inhibitor
  • Non-Small Cell Lung Cancer Capmatinib (INC280) Phase 2 c-MET RTK inhibitor
  • Non-Small Cell Lung Cancer Alpelisib (BYL719) Phase 2 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Non-Small Cell Lung Cancer PBF509 Phase 1/Phase 2 An A2A adenosine receptor antagonist
  • Non-Small Cell Lung Cancer EGF816 Phase 1 Selectively inhibiting mutant epidermal growth factor receptor (EGFRmut)
  • Non-Small Cell Lung Cancer EGF816 Phase 1/Phase 2 Selectively inhibiting mutant epidermal growth factor receptor (EGFRmut)
  • Non-Small Cell Lung Cancer EGF816 Phase 2 Selectively inhibiting mutant epidermal growth factor receptor (EGFRmut)
  • Non-Small Cell Lung Cancer LAG525 A LAG-3 receptor-targeting monoclonal antibody
  • Non-Small Cell Lung Cancer Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Non-Small Cell Lung Cancer Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • OVARIAN CANCER
  • Ovarian Cancer Alpelisib (BYL719) Phase 1 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • PANCREATIC CANCER
  • Pancreatic Cancer Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Pancreatic Cancer Alpelisib (BYL719) Phase 1 Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • Pancreatic Cancer Buparlisib (BKM120) Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • PROSTATE CANCER
  • Prostate Cancer Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)
  • Prostate Cancer Buparlisib (BKM120) Phase 1 Inhibiting All 4 Isoforms of Class I Phosphatidylinositol 3-Kinase (PI3K)
  • Prostate Cancer Afuresertib (ASB183) A pan-AKT kinase inhibitor
  • RENAL CELL CARCINOMA
  • Renal Cell Carcinoma LAG525 A LAG-3 receptor-targeting monoclonal antibody
  • Renal Cell Carcinoma Alpelisib (BYL719) Targeting Solid Tumors With an Alpha-Specific Inhibitor of Phosphatidylinositol 3-Kinase (PI3K)
  • SARCOMA
  • Sarcoma Ribociclib (LEE011) Phase 1/Phase 2 Inhibiting Cyclin-Dependent Kinases 4 and 6 (CDK4/6)

All compounds are either investigational or studied in new indications. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.